Tcg Crossover Management, LLC Iveric Bio, Inc. Transaction History

Tcg Crossover Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$26.24 - $39.63 $70.6 Million - $107 Million	-2,692,289 Reduced 52.37%	2,448,829 $96.3 Million
Q4 2022 Feb 14, 2023	BUY	$17.24 - $23.95 $21.8 Million - $30.3 Million	1,263,215 Added 32.57%	5,141,118 $110 Million
Q3 2022 Nov 14, 2022	BUY	$9.4 - $18.59 $9.06 Million - $17.9 Million	963,653 Added 33.07%	3,877,903 $69.6 Million
Q2 2022 Aug 15, 2022	BUY	$9.12 - $18.9 $3.62 Million - $7.51 Million	397,330 Added 15.79%	2,914,250 $28 Million
Q1 2022 May 16, 2022	BUY	$12.15 - $16.83 $9.42 Million - $13.1 Million	775,692 Added 44.55%	2,516,920 $42.4 Million
Q4 2021 Feb 18, 2022	BUY	$13.83 - $18.78 $24.1 Million - $32.7 Million	1,741,228 New	1,741,228 $29.1 Million

250K

40K

Ticker ISEE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,078,000
Description
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 cl...

Get notified when there are updates to the investment portfolio of Tcg Crossover Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Tcg Crossover Management, LLC with notifications on news.